Misonix Incorporated Establishes New Contract Sales Organization for Distribution of SonicOne(TM) Wound Management System in the United Sates

FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (NASDAQ: MSON - News), a developer of minimally invasive ultrasonic medical device technology, which, in Europe is used for the ablation of cancer and worldwide for other acute health conditions, today announced the formation of a new sales channel for the United States. The Company expects to assemble a team of approximately 25 contract sales agents that will sell Misonix labeled product, on a commission only basis, directly to hospitals and clinics throughout the US. The SonicOne™ Wound Management System will be the first product sold by this new sales team. SonicOne is a tissue specific wound cleansing and debridement system, effective for the removal of devitalized or necrotic tissue and fibrin deposits, which ensures progress toward patient healing. The first six sales agents are under contract and will complete training by the end of June 2008. Exclusive sales territories represented by these six representatives include Metropolitan New York City, Metropolitan Chicago, Wisconsin, Texas, Kentucky, and Southern Ohio.

Misonix has appointed Mr. E.Y. Denard, Director of Sales for the Americas, an industry veteran, to recruit, train, and manage this sales group. Mr. Denard has more than 25 years of successful healthcare sales experience, encompassing disposable medical devices, capital equipment, and product service. Mr. Denard’s has both domestic and international sales experience and he will assist the Company with proprietary distribution throughout North and South America.

“Misonix is pleased to add someone with Mr. Denard’s track record of success to our sales organization,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.” The establishment of this sales group is designed to increase our market penetration and revenue potential for this important new product and to build customer awareness and brand equity for Misonix in the US. Additionally, we believe that this sales team, which is highly experienced in the sale of medical equipment and disposables, will provide us with the capability to more effectively sell other Misonix labeled product to US clinical customers in the years to come.”

About Misonix:

Misonix, Inc. (NASDAQ: MSON - News) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc., which uses high intensity focused ultrasound technology in prostate procedures. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Contact: Misonix, Inc. Richard Zaremba, 631-694-9555 invest@misonix.com or

Investor Relations: Cameron Associates, Inc. 212-245-4577 Kevin@cameronassoc.com

Source: Misonix, Inc.